Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 9.187
1.
Clin Nucl Med ; 49(7): 637-643, 2024 Jul 01.
Article En | MEDLINE | ID: mdl-38831512

BACKGROUND: This meta-analysis and systematic review assessed the diagnostic accuracy of lung SPECT compared with lung planar imaging in patients with suspected acute pulmonary embolism (PE) or chronic thromboembolic pulmonary hypertension. PATIENTS AND METHODS: A search of Medline, Embase, and Cochrane databases identified suitable articles published before October 2023. Meta-analyses were performed to determine the diagnostic accuracy of SPECT imaging modalities, including perfusion (Q) SPECT, ventilation (V)/Q SPECT, Q SPECT/CT, and V/Q SPECT/CT. Network meta-analyses were performed to compare the diagnostic accuracy of SPECT and planar imaging in paired-design studies. RESULTS: Twenty-four articles (total n = 6576) were included in the analysis. For suspected acute PE, the respective sensitivity and specificity of SPECT imaging modalities were as follows: Q SPECT, 0.93 (95% confidence interval [CI], 0.87-0.99; I2 = 49%) and 0.72 (95% CI, 0.54-0.95; I2 = 94%); V/Q SPECT, 0.96 (95% CI, 0.94-0.98; I2 = 51%) and 0.95 (95% CI, 0.92-0.98; I2 = 80%); Q SPECT/CT, 0.93 (95% CI, 0.87-0.98; I2 = 66%) and 0.82 (95% CI, 0.70-0.96; I2 = 87%); and V/Q SPECT/CT, 0.97 (95% CI, 0.93-1.00; I2 = 7%) and 0.98 (95% CI, 0.97-1.00; I2 = 31%). The relative sensitivity and specificity of SPECT compared with planar imaging were 1.17 (95% CI, 1.06-1.30; P < 0.001) and 1.14 (95% CI, 1.00-1.29; P = 0.05), respectively. For suspected chronic thromboembolic pulmonary hypertension, the pooled sensitivity and specificity of SPECT imaging were 0.97 (95% CI, 0.95-1.00; I2 = 0%) and 0.91 (95% CI, 0.87-0.94; I2 = 0%), respectively. CONCLUSIONS: SPECT exhibited superior diagnostic performance for PE. V/Q SPECT/CT was the most accurate modality.


Pulmonary Embolism , Tomography, Emission-Computed, Single-Photon , Pulmonary Embolism/diagnostic imaging , Humans , Network Meta-Analysis
2.
Tidsskr Nor Laegeforen ; 144(7)2024 Jun 04.
Article En, Nor | MEDLINE | ID: mdl-38832610

Background: While most cases of venous thromboembolism follow a benign course, occasionally the condition may manifest a complex clinical presentation and need a comprehensive diagnostic workup to identify the underlying cause and provide the patient with appropriate treatment. Case presentation: A woman in her late thirties presented to the emergency department with a five-day history of dyspnoea. She had recently undergone liposuction surgery after pregnancy. Upon admission, initial investigations revealed a pulmonary embolism with right heart strain, and she was treated with anticoagulants. The following day, she complained of acute-onset right flank pain without fever or other accompanying symptoms. A CT scan of the abdomen confirmed a right-side renal infarction. Further investigations revealed patent foramen ovale between the right and left atria of the heart, believed to be the source of a right-to-left shunt of arterial emboli. Although the patient had not suffered a clinical stroke, it was decided to close this defect using percutaneous technique. Interpretation: Patent foramen ovale is a common condition in adults, but in most cases it remains asymptomatic. However, patients with patent foramen ovale have an elevated risk of arterial emboli affecting multiple organs. The diagnosis depends on thorough assessment to prevent potentially fatal outcomes.


Abdominoplasty , Dyspnea , Foramen Ovale, Patent , Pulmonary Embolism , Humans , Female , Adult , Foramen Ovale, Patent/complications , Foramen Ovale, Patent/surgery , Foramen Ovale, Patent/diagnostic imaging , Dyspnea/etiology , Abdominoplasty/adverse effects , Pulmonary Embolism/etiology , Pulmonary Embolism/diagnostic imaging , Tomography, X-Ray Computed , Infarction/etiology , Infarction/diagnostic imaging , Infarction/diagnosis , Infarction/surgery , Postoperative Complications
3.
Article En | MEDLINE | ID: mdl-38765212

The presentation of pulmonary embolism (PE) varies from asymptomatic to life-threatening, and management involves multiple specialists. Timely diagnosis of PE is based on clinical presentation, D-dimer testing, and computed tomography pulmonary angiogram (CTPA), and assessment by a Pulmonary Embolism Response Team (PERT) is critical to management. Artificial intelligence (AI) technology plays a key role in the PE workflow with automated detection and flagging of suspected PE in CTPA imaging. HIPAA-compliant communication features of mobile and web-based applications may facilitate PERT workflow with immediate access to imaging, team activation, and real-time information sharing and collaboration. In this review, we describe contemporary diagnostic tools, specifically AI, that are important in the triage and diagnosis of PE.


Artificial Intelligence , Biomarkers , Computed Tomography Angiography , Fibrin Fibrinogen Degradation Products , Predictive Value of Tests , Pulmonary Embolism , Humans , Pulmonary Embolism/diagnostic imaging , Pulmonary Embolism/diagnosis , Fibrin Fibrinogen Degradation Products/analysis , Fibrin Fibrinogen Degradation Products/metabolism , Biomarkers/blood , Workflow , Prognosis , Radiographic Image Interpretation, Computer-Assisted , Pulmonary Artery/diagnostic imaging , Pulmonary Artery/physiopathology
4.
Methodist Debakey Cardiovasc J ; 20(3): 19-26, 2024.
Article En | MEDLINE | ID: mdl-38765213

Massive pulmonary embolism (MPE) is a serious condition affecting the pulmonary arteries and is difficult to diagnose, triage, and treat. The American College of Chest Physicians (AHA) and the European Society of Cardiology (ESC) have different classification approaches for PE, with the AHA defining three subtypes and the ESC four. Misdiagnosis is common, leading to delayed or inadequate treatment. The incidence of PE-related death rates has been increasing over the years, and mortality rates vary depending on the subtype of PE, with MPE having the highest mortality rate. The current definition of MPE originated from early surgical embolectomy cases and discussions among experts. However, this definition fails to capture patients at the point of maximal benefit because it is based on late findings of MPE. Pulmonary Embolism Response Teams (PERTs) have emerged as a fundamental shift in the management of MPE, with a focus on high-risk and MPE cases and a goal of rapidly connecting patients with appropriate therapies based on up-to-date evidence. This review highlights the challenges in diagnosing and managing MPE and emphasizes the importance of PERTs and risk stratification scores in improving outcomes for patients with PE.


Predictive Value of Tests , Pulmonary Embolism , Pulmonary Embolism/therapy , Pulmonary Embolism/mortality , Pulmonary Embolism/diagnosis , Pulmonary Embolism/diagnostic imaging , Pulmonary Embolism/physiopathology , Humans , Treatment Outcome , Risk Factors , Risk Assessment , Clinical Decision-Making , Embolectomy/adverse effects , Decision Support Techniques , Thrombolytic Therapy , Patient Care Team
5.
Methodist Debakey Cardiovasc J ; 20(3): 13-18, 2024.
Article En | MEDLINE | ID: mdl-38765214

With a multitude of options for pulmonary embolism management, we review the most common diagnostic tools available for assessing risk as well as how each broad risk category is typically treated. Right heart dysfunction is the cornerstone for triage of these patients and should be the focus for decision-making, especially in challenging patients. We aim to provide a modern, clinical perspective for PE management in light of the multitude of intervention options.


Clinical Decision-Making , Pulmonary Embolism , Pulmonary Embolism/therapy , Pulmonary Embolism/diagnosis , Pulmonary Embolism/physiopathology , Pulmonary Embolism/diagnostic imaging , Humans , Risk Factors , Treatment Outcome , Risk Assessment , Predictive Value of Tests , Thrombolytic Therapy/adverse effects , Embolectomy , Endovascular Procedures/adverse effects , Anticoagulants/therapeutic use , Anticoagulants/adverse effects , Patient Selection , Thrombectomy
6.
Methodist Debakey Cardiovasc J ; 20(3): 36-48, 2024.
Article En | MEDLINE | ID: mdl-38765215

Pulmonary embolism is a debilitating and potentially life-threatening disease characterized by high mortality and long-term adverse outcomes. Traditional treatment options are fraught with serious bleeding risks and incomplete thrombus removal, necessitating the development of innovative treatment strategies. While new interventional approaches offer promising potential for improved outcomes with fewer serious complications, their rapid development and need for more comparative clinical evidence makes it challenging for physicians to select the optimal treatment for each patient among the many options. This review summarizes the current published clinical data for both traditional treatments and more recent interventional approaches indicated for pulmonary embolism. While published studies thus far suggest that these newer interventional devices offer safe and effective options, more data is needed to understand their impact relative to the standard of care. The studies in progress that are anticipated to provide needed evidence are reviewed here since they will be critical for helping physicians make informed treatment choices and potentially driving necessary guideline changes.


Fibrinolytic Agents , Pulmonary Embolism , Thrombectomy , Thrombolytic Therapy , Humans , Clinical Decision-Making , Equipment Design , Fibrinolytic Agents/administration & dosage , Fibrinolytic Agents/adverse effects , Pulmonary Embolism/therapy , Pulmonary Embolism/diagnostic imaging , Pulmonary Embolism/mortality , Risk Factors , Thrombectomy/adverse effects , Thrombectomy/instrumentation , Thrombolytic Therapy/adverse effects , Treatment Outcome
7.
Methodist Debakey Cardiovasc J ; 20(3): 65-67, 2024.
Article En | MEDLINE | ID: mdl-38765217

Anticoagulation has been the standard therapy for treating pulmonary embolism. However, newly developed pharmacological and interventional treatment options have been shown to provide benefit for certain patient populations, depending on how they present. This column highlights the use of massive pulmonary embolism risk stratification in determining the presence of cor pulmonale and offers several key points to remember when caring for patients with a pulmonary embolism.


Anticoagulants , Clinical Decision-Making , Pulmonary Embolism , Triage , Humans , Anticoagulants/therapeutic use , Decision Support Techniques , Patient Selection , Predictive Value of Tests , Pulmonary Embolism/therapy , Pulmonary Embolism/diagnostic imaging , Pulmonary Embolism/diagnosis , Pulmonary Embolism/physiopathology , Risk Assessment , Risk Factors , Thrombolytic Therapy , Treatment Outcome , Male , Aged
9.
BMJ Open ; 14(5): e075712, 2024 May 15.
Article En | MEDLINE | ID: mdl-38754880

INTRODUCTION: Pulmonary embolism (PE) is a challenge to diagnose and when missed, exposes patients to potentially fatal recurrent events. Beyond CT pulmonary angiography (CTPA) and planar ventilation/perfusion (V/Q) scan, single photon emission CT (SPECT) V/Q emerged a new diagnostic modality of scintigraphic acquisition that has been reported to improve diagnostic performances. To date, no management outcome study or randomised trial evaluated an algorithm based on SPECT V/Q for PE diagnosis. We present the design of a randomised multicentre, international management study comparing SPECT V/Q with validated strategies. MATERIAL AND METHODS: We will include a total of 3672 patients with suspected PE requiring chest imaging, randomised into three different groups, each using a different diagnostic strategy based on SPECT V/Q, CTPA and planar V/Q scan. Randomisation will be unbalanced (2:1:1), with twice as many patients in SPECT V/Q arm (n=1836) as in CTPA and planar V/Q arms (n=918 in each). Our primary objective will be to determine whether a diagnostic strategy based on SPECT V/Q is non-inferior to previously validated strategies in terms of diagnostic exclusion safety as assessed by the 3-month risk of thromboembolism in patients with a negative diagnostic workup. Secondary outcomes will be the proportion of patients diagnosed with PE in each arm, patients requiring additional tests, the incidence of major and clinically relevant non-major bleeding and the incidence and cause of death in each arm. ETHICS AND DISSEMINATION: This trial is funded by a grant from Brest University Hospital and by INVENT. The study protocol was approved by Biomedical Research Ethics Committee. The investigator or delegate will obtain signed informed consent from all patients prior to inclusion in the trial. Our results will inform future clinical practice guidelines and solve the current discrepancy between nuclear medicine guidelines and clinical scientific society guidelines. TRIAL REGISTRATION NUMBER: NCT02983760.


Computed Tomography Angiography , Pulmonary Embolism , Tomography, Emission-Computed, Single-Photon , Ventilation-Perfusion Scan , Pulmonary Embolism/diagnostic imaging , Humans , Computed Tomography Angiography/methods , Tomography, Emission-Computed, Single-Photon/methods , Ventilation-Perfusion Scan/methods , Randomized Controlled Trials as Topic , Female , Male , Ventilation-Perfusion Ratio
10.
Clin Chest Med ; 45(2): 405-418, 2024 Jun.
Article En | MEDLINE | ID: mdl-38816096

Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication of pulmonary embolism and is an important cause of pulmonary hypertension. As a clinical entity, it is frequently underdiagnosed with prolonged diagnostic delays. This study reviews the clinical and radiographic findings associated with CTEPH to improve awareness and recognition. Strengths and limitations of multiple imaging modalities are reviewed. Accompanying images are provided to supplement the text and provide examples of important findings for the reader.


Hypertension, Pulmonary , Pulmonary Embolism , Humans , Hypertension, Pulmonary/diagnostic imaging , Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/etiology , Hypertension, Pulmonary/physiopathology , Pulmonary Embolism/diagnostic imaging , Pulmonary Embolism/complications , Pulmonary Embolism/diagnosis , Chronic Disease , Pulmonary Artery/diagnostic imaging , Echocardiography/methods
11.
Ann Card Anaesth ; 27(1): 68-69, 2024 Jan 01.
Article En | MEDLINE | ID: mdl-38722126

ABSTRACT: The occurrence of pulmonary artery thrombus in association with rheumatic mitral stenosis is a rare complication. Pulmonary artery thrombus formation may worsen pulmonary artery pressures, and this may precipitate acute right heart failure. The possible mechanisms behind pulmonary artery thrombus formation during mitral valve replacement surgery could be acute coagulopathy following surgery, the presence of chronic pulmonary thromboembolism, or chronic atrial fibrillation. We report an unusual case of pulmonary artery thrombus in a patient with rheumatic MS which was diagnosed with transoesophageal echocardiography after MVR.


Delayed Diagnosis , Echocardiography, Transesophageal , Heart Valve Prosthesis Implantation , Mitral Valve , Pulmonary Artery , Thrombosis , Humans , Heart Valve Prosthesis Implantation/adverse effects , Pulmonary Artery/diagnostic imaging , Echocardiography, Transesophageal/methods , Thrombosis/diagnostic imaging , Thrombosis/etiology , Mitral Valve/surgery , Mitral Valve/diagnostic imaging , Mitral Valve Stenosis/surgery , Female , Rheumatic Heart Disease/complications , Rheumatic Heart Disease/surgery , Pulmonary Embolism/etiology , Pulmonary Embolism/diagnostic imaging , Middle Aged
14.
Sci Rep ; 14(1): 11919, 2024 05 24.
Article En | MEDLINE | ID: mdl-38789497

The purpose of this study was to evaluate pre-treatment CT findings in patients with acute pulmonary embolism (PE) and determine the imaging findings associated with residual hypoperfused segments in post-treatment lung perfused blood volume (LPBV). We evaluated 91 patients with acute PE who underwent dual-energy CT before and after treatment. The location of thrombi (proximal or distal) and patency of the pulmonary artery (occlusive or non-occlusive) were recorded using pre-treatment computed tomography pulmonary angiography (CTPA). Residual hypoperfusion was defined as a perfusion-decreased area seen in both the pre- and post-treatment LPBVs. The association of the location of the thrombus and vascular patency of pre-treatment CTPA with residual hypoperfusion on a segmental and patient basis was examined. In the segment-based analysis, the proportion of residual hypoperfusion in the proximal group was significantly higher than that in the peripheral group (33/125 [26.4%] vs. 9/87 [10.3%], P = 0.004). Patient-based analysis also showed that the proportion of residual hypoperfusion in patients with pre-treatment proximal thrombus was significantly higher than those without (16/42 [38.1%] vs. 3/25 (12.0%); P = 0.022). Pre-treatment vascular patency was not significantly associated with residual hypoperfusion (P > 0.05). Therefore, careful follow-up is necessary, especially in patients with proximal thrombi.


Blood Volume , Lung , Pulmonary Embolism , Tomography, X-Ray Computed , Humans , Male , Female , Middle Aged , Aged , Pulmonary Embolism/diagnostic imaging , Lung/diagnostic imaging , Lung/blood supply , Tomography, X-Ray Computed/methods , Pulmonary Artery/diagnostic imaging , Pulmonary Artery/physiopathology , Adult , Aged, 80 and over , Retrospective Studies , Thrombosis/diagnostic imaging , Computed Tomography Angiography/methods
15.
Tunis Med ; 102(5): 315-320, 2024 May 05.
Article En | MEDLINE | ID: mdl-38801291

INTRODUCTION: The occurrence of death from acute pulmonary embolism (PE) is often linked to right ventricular (RV) failure, arising from an imbalance between RV systolic function and heightened RV afterload. In our study, we posited that an echocardiographic ratio derived from this disparity [RV systolic function assessed by tricuspid annular plane systolic excursion (TAPSE) divided by pulmonary arterial systolic pressure (PASP)] could offer superior predictive value for adverse outcomes compared to individual measurements of TAPSE and PASP alone. METHODS: We conducted a retrospective analysis using data from a University Hospital Centre spanning from 2017 to 2023. All individuals with confirmed PE and a formal transthoracic echocardiogram within 7 days of diagnosis were included. The primary endpoint was a composite outcome of death, hemodynamic deterioration needing introduction of inotropes or thrombolysis within 30 days. Secondary endpoints included 6 months all-cause mortality and onset of right-sided heart failure. RESULTS: Thirty-eight patients were included. Mean age was 58 ±15 years old. A male predominance was noted: 23 male patients (60.5%) and 15 female patients (39.5%). Eight patients met the primary composite endpoint while nine patients met the secondary composite endpoint. In multivariate analysis, the TAPSE/PASP ratio was independently associated with the primary outcome (OR=2.77, 95% CI 1.101-10.23, P=0.042). A TAPSE/PASP ratio <0.3 was independently associated with the secondary outcome (OR=3.07, 95% CI 1.185-10.18, P=0.034). CONCLUSION: This study suggests that a combined echocardiographic ratio of RV function to afterload is effective in predicting adverse outcomes in acute PE.


Echocardiography , Pulmonary Artery , Pulmonary Embolism , Tricuspid Valve , Humans , Pulmonary Embolism/diagnosis , Pulmonary Embolism/physiopathology , Pulmonary Embolism/mortality , Pulmonary Embolism/complications , Pulmonary Embolism/diagnostic imaging , Female , Male , Middle Aged , Retrospective Studies , Prognosis , Aged , Echocardiography/methods , Pulmonary Artery/diagnostic imaging , Pulmonary Artery/physiopathology , Acute Disease , Adult , Tricuspid Valve/diagnostic imaging , Tricuspid Valve/physiopathology , Ventricular Dysfunction, Right/diagnosis , Ventricular Dysfunction, Right/physiopathology , Ventricular Dysfunction, Right/diagnostic imaging , Ventricular Dysfunction, Right/etiology , Predictive Value of Tests , Systole/physiology
16.
Thromb Res ; 238: 105-116, 2024 Jun.
Article En | MEDLINE | ID: mdl-38703584

The first-choice imaging test for visualization of thromboemboli in the pulmonary vasculature in patients with suspected acute pulmonary embolism (PE) is multidetector computed tomography pulmonary angiography (CTPA) - a readily available and widely used imaging technique. Through technological advancements over the past years, alternative imaging techniques for the diagnosis of PE have become available, whilst others are still under investigation. In particular, the evolution of artificial intelligence (AI) is expected to enable further innovation in diagnostic management of PE. In this narrative review, current CTPA techniques and the emerging technology photon-counting CT (PCCT), as well as other modern imaging techniques of acute PE are discussed, including CTPA with iodine maps based on subtraction or dual-energy acquisition, single-photon emission CT (SPECT), magnetic resonance angiography (MRA), and magnetic resonance direct thrombus imaging (MRDTI). Furthermore, potential applications of AI are discussed.


Pulmonary Embolism , Pulmonary Embolism/diagnostic imaging , Humans , Acute Disease , Computed Tomography Angiography/methods
17.
Emerg Radiol ; 31(3): 321-330, 2024 Jun.
Article En | MEDLINE | ID: mdl-38619803

BACKGROUND: Sickle cell disease (SCD) is a genetic hematological disorder associated with severe complications, such as vaso-occlusive crises, acute chest syndrome (ACS), and an increased risk of thromboembolic events, including pulmonary embolism (PE). The diagnosis of PE in SCD patients presents challenges due to the overlapping symptoms with other pulmonary conditions. Our previous study revealed that nearly 96% of computed tomography pulmonary angiography (CTPA) scans in SCD patients were negative for PE, highlighting a gap in understanding the significance of CTPA findings when PE is absent. METHODS: In this retrospective follow-up study conducted at the Salmaniya Medical Complex in Bahrain, we examined SCD patients with HbSS genotypes who underwent CTPA from January 1, 2018, to December 31, 2021, for suspected PE, but the results were negative. The aim of this study was to identify alternative diagnoses and incidental findings from CTPA scans. Experienced radiologists reviewed the CTPA images and reports to assess potential alternative diagnoses and incidental findings, incorporating an additional analysis of chest X-rays to evaluate the diagnostic value of CTPA. Incidental findings were classified based on their location and clinical significance. RESULTS: Among the 230 evaluated SCD patients (average age 39.7 years; 53% male) who were CTPA negative for PE, 142 (61.7%) had identifiable alternative diagnoses, primarily pneumonia (49.1%). Notably, 88.0% of these alternative diagnoses had been previously suggested by chest radiographs. Furthermore, incidental findings were noted in 164 (71.3%) patients, with 11.0% deemed clinically significant, necessitating immediate action, and 87.8% considered potentially significant, requiring further assessment. Notable incidental findings included thoracic abnormalities such as cardiomegaly (12.2%) and an enlarged pulmonary artery (11.3%), as well as upper abdominal pathologies such as hepatomegaly (19.6%), splenomegaly (20.9%), and gallstones (10.4%). CONCLUSION: This study underscores the limited additional diagnostic yield of CTPA for identifying alternative diagnoses to PE in SCD patients, with the majority of diagnoses, such as pneumonia, already suggested by chest radiographs. The frequent incidental findings, most of which necessitate further evaluation, highlight the need for a cautious and tailored approach to using CTPA in the SCD population.


Anemia, Sickle Cell , Computed Tomography Angiography , Incidental Findings , Pulmonary Embolism , Humans , Anemia, Sickle Cell/diagnostic imaging , Anemia, Sickle Cell/complications , Male , Female , Pulmonary Embolism/diagnostic imaging , Retrospective Studies , Adult , Diagnosis, Differential , Follow-Up Studies , Middle Aged
18.
Respir Res ; 25(1): 164, 2024 Apr 15.
Article En | MEDLINE | ID: mdl-38622598

BACKGROUND: Balloon pulmonary angioplasty (BPA) improves the prognosis of chronic thromboembolic pulmonary hypertension (CTEPH). Right ventricle (RV) is an important predictor of prognosis in CTEPH patients. 2D-speckle tracking echocardiography (2D-STE) can evaluate RV function. This study aimed to evaluate the effectiveness of BPA in CTEPH patients and to assess the value of 2D-STE in predicting outcomes of BPA. METHODS: A total of 76 patients with CTEPH underwent 354 BPA sessions from January 2017 to October 2022. Responders were defined as those with mean pulmonary artery pressure (mPAP) ≤ 30 mmHg or those showing ≥ 30% decrease in pulmonary vascular resistance (PVR) after the last BPA session, compared to baseline. Logistic regression analysis was performed to identify predictors of BPA efficacy. RESULTS: BPA resulted in a significant decrease in mPAP (from 50.8 ± 10.4 mmHg to 35.5 ± 11.9 mmHg, p < 0.001), PVR (from 888.7 ± 363.5 dyn·s·cm-5 to 545.5 ± 383.8 dyn·s·cm-5, p < 0.001), and eccentricity index (from 1.3 to 1.1, p < 0.001), and a significant increase in RV free wall longitudinal strain (RVFWLS: from 15.7% to 21.0%, p < 0.001). Significant improvement was also observed in the 6-min walking distance (from 385.5 m to 454.5 m, p < 0.001). After adjusting for confounders, multivariate analysis showed that RVFWLS was the only independent predictor of BPA efficacy. The optimal RVFWLS cutoff value for predicting BPA responders was 12%. CONCLUSIONS: BPA was found to reduce pulmonary artery pressure, reverse RV remodeling, and improve exercise capacity. RVFWLS obtained by 2D-STE was an independent predictor of BPA outcomes. Our study may provide a meaningful reference for interventional therapy of CTEPH.


Angioplasty, Balloon , Hypertension, Pulmonary , Pulmonary Embolism , Humans , Hypertension, Pulmonary/diagnostic imaging , Hypertension, Pulmonary/therapy , Pulmonary Embolism/diagnostic imaging , Pulmonary Embolism/therapy , Ventricular Remodeling , Echocardiography , Chronic Disease , Pulmonary Artery/diagnostic imaging
19.
Sci Rep ; 14(1): 8741, 2024 04 16.
Article En | MEDLINE | ID: mdl-38627583

Pulmonary embolism is a potentially fatal condition with increased mortality if anticoagulation is delayed. This study aimed to find influencing factors on the duration from requesting a computed tomography (CT) pulmonary angiography (CTPA) to performing a CTPA in suspected acute pulmonary embolism. In 1849 cases, automatically generated time data were extracted from the radiological information system. The impact of the distance to the scanner, case-related features (sector of patient care, triage), and workload (demand for CTs, performed CTs, available staff, hospital occupancy) were investigated retrospectively using multiple regression. The time to CTPA was shorter in cases from the emergency room (ER) than in inpatients and outpatients at distances below 160 m and 240 m, respectively. While requests from the ER were also performed faster than cases from regular wards (< 180 m), no difference was found between the ER and intensive care units. Compared to "not urgent" cases, the workflow was shorter in "urgent" (- 17%) and "life-threatening" (- 67%) situations. The process was prolonged with increasing demand (+ 5%/10 CTs). The presented analysis identified relevant in-hospital influences on the CTPA workflow, including the distance to the CT together with the sector of patient care, the case triage, and the demand for imaging.


Pulmonary Embolism , Tomography, X-Ray Computed , Humans , Retrospective Studies , Tomography, X-Ray Computed/methods , Pulmonary Embolism/diagnostic imaging , Computed Tomography Angiography/methods , Angiography/methods
20.
PLoS One ; 19(4): e0300716, 2024.
Article En | MEDLINE | ID: mdl-38578764

BACKGROUND AND PURPOSE: Mean pulmonary artery pressure (mPAP) is a key index for chronic thromboembolic pulmonary hypertension (CTEPH). Using machine learning, we attempted to construct an accurate prediction model for mPAP in patients with CTEPH. METHODS: A total of 136 patients diagnosed with CTEPH were included, for whom mPAP was measured. The following patient data were used as explanatory variables in the model: basic patient information (age and sex), blood tests (brain natriuretic peptide (BNP)), echocardiography (tricuspid valve pressure gradient (TRPG)), and chest radiography (cardiothoracic ratio (CTR), right second arc ratio, and presence of avascular area). Seven machine learning methods including linear regression were used for the multivariable prediction models. Additionally, prediction models were constructed using the AutoML software. Among the 136 patients, 2/3 and 1/3 were used as training and validation sets, respectively. The average of R squared was obtained from 10 different data splittings of the training and validation sets. RESULTS: The optimal machine learning model was linear regression (averaged R squared, 0.360). The optimal combination of explanatory variables with linear regression was age, BNP level, TRPG level, and CTR (averaged R squared, 0.388). The R squared of the optimal multivariable linear regression model was higher than that of the univariable linear regression model with only TRPG. CONCLUSION: We constructed a more accurate prediction model for mPAP in patients with CTEPH than a model of TRPG only. The prediction performance of our model was improved by selecting the optimal machine learning method and combination of explanatory variables.


Hypertension, Pulmonary , Pulmonary Embolism , Humans , Hypertension, Pulmonary/diagnosis , Arterial Pressure , Echocardiography/methods , Tricuspid Valve , Natriuretic Peptide, Brain , Pulmonary Embolism/complications , Pulmonary Embolism/diagnostic imaging , Chronic Disease
...